Literature DB >> 15808807

Aldosterone as a cardiovascular risk factor.

GianPaolo Rossi1, Marco Boscaro, Vanessa Ronconi, John W Funder.   

Abstract

Aldosterone exerts cardiovascular effects by influencing epithelial fluid and electrolyte excretion, and thus blood volume and pressure. Mineralocorticoid receptors (MR) are found in epithelial and non-epithelial tissues (vessel walls, heart, brain), with high affinity for aldosterone and physiological glucocorticoids cortisol and corticosterone. MR blockade by spironolactone or eplerenone favorably affects cardiovascular outcomes. In some situations (primary aldosteronism, experimental mineralocorticoid administration) activation of cardiovascular MR reflects aldosterone levels inappropriate for salt status. In others (heart failure, essential hypertension) aldosterone and Na(+) status are often normal pretreatment; cardiovascular MR may thus be activated by normal glucocorticoid levels after tissue damage and reactive oxygen species generation. Therefore, although unilateral adrenalectomy is preferred therapy for unilateral aldosterone-producing adenoma or hyperplasia, MR blockade may be useful in cardiovascular diseases where aldosterone levels are normal.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15808807     DOI: 10.1016/j.tem.2005.02.010

Source DB:  PubMed          Journal:  Trends Endocrinol Metab        ISSN: 1043-2760            Impact factor:   12.015


  29 in total

1.  Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease.

Authors:  Alessia Buglioni; Valentina Cannone; Alessandro Cataliotti; S Jeson Sangaralingham; Denise M Heublein; Christopher G Scott; Kent R Bailey; Richard J Rodeheffer; Paolo Dessì-Fulgheri; Riccardo Sarzani; John C Burnett
Journal:  Hypertension       Date:  2014-11-03       Impact factor: 10.190

2.  Mechanisms of endothelin-1-induced MAP kinase activation in adrenal glomerulosa cells.

Authors:  Bukhtiar H Shah; Albert J Baukal; Hung-Dar Chen; Ali B Shah; Kevin J Catt
Journal:  J Steroid Biochem Mol Biol       Date:  2006-12       Impact factor: 4.292

Review 3.  The role of aldosterone in cardiovascular disease in people with diabetes and hypertension: an update.

Authors:  Guido Lastra-Gonzalez; Camila Manrique-Acevedo; James R Sowers
Journal:  Curr Diab Rep       Date:  2008-06       Impact factor: 4.810

Review 4.  New insights into insulin action and resistance in the vasculature.

Authors:  Camila Manrique; Guido Lastra; James R Sowers
Journal:  Ann N Y Acad Sci       Date:  2014-03-20       Impact factor: 5.691

5.  Systolic heart failure in a patient with primary aldosteronism.

Authors:  Chikezie Alvarez; Vinuta Mohan
Journal:  BMJ Case Rep       Date:  2018-06-08

6.  Kininogen gene (KNG) variation has a consistent effect on aldosterone response to antihypertensive drug therapy: the GERA study.

Authors:  Maja Barbalic; Gary L Schwartz; Arlene B Chapman; Stephen T Turner; Eric Boerwinkle
Journal:  Physiol Genomics       Date:  2009-07-07       Impact factor: 3.107

Review 7.  Mineralocorticoid antagonism and cardiac hypertrophy.

Authors:  Kohzo Nagata
Journal:  Curr Hypertens Rep       Date:  2008-06       Impact factor: 5.369

8.  Cardiac remodeling in patients with primary aldosteronism.

Authors:  F Galetta; G Bernini; F Franzoni; A Bacca; I Fivizzani; L Tocchini; M Bernini; P Fallahi; A Antonelli; G Santoro
Journal:  J Endocrinol Invest       Date:  2009-10       Impact factor: 4.256

9.  Shortened saline infusion test for subtype prediction in primary aldosteronism.

Authors:  Kazutaka Nanba; Mika Tsuiki; Hironobu Umakoshi; Aya Nanba; Yuusuke Hirokawa; Takeshi Usui; Tetsuya Tagami; Akira Shimatsu; Tomoko Suzuki; Akiyo Tanabe; Mitsuhide Naruse
Journal:  Endocrine       Date:  2015-05-01       Impact factor: 3.633

10.  Intrarenal hemodynamics in primary aldosteronism before and after treatment.

Authors:  Leonardo A Sechi; Alessandro Di Fabio; Massimo Bazzocchi; Alessandro Uzzau; Cristiana Catena
Journal:  J Clin Endocrinol Metab       Date:  2009-01-13       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.